Aranesp Approved for Extended Dosing by European Commission Read more about Aranesp Approved for Extended Dosing by European Commission
Amgen Names Arvind Sood Vice President, Investor Relations Read more about Amgen Names Arvind Sood Vice President, Investor Relations
Amgen Completes Acquisition of Tularik; Acquisition Enhances Amgen's Strong Research Organization and Establishes Amgen in the San Francisco Bay Area Read more about Amgen Completes Acquisition of Tularik; Acquisition Enhances Amgen's Strong Research Organization and Establishes Amgen in the San Francisco Bay Area
First Patients Dosed with Amgen's AMG 162 In Phase 3 Studies for Postmenopausal Osteoporosis and Treatment-Induced Bone Loss Read more about First Patients Dosed with Amgen's AMG 162 In Phase 3 Studies for Postmenopausal Osteoporosis and Treatment-Induced Bone Loss
Aranesp Receives Positive Regulatory Opinion for Extended Dosing in Europe Read more about Aranesp Receives Positive Regulatory Opinion for Extended Dosing in Europe
Mimpara -- Cinacalcet HCl -- Receives Positive Regulatory Opinion for Approval in Europe Read more about Mimpara -- Cinacalcet HCl -- Receives Positive Regulatory Opinion for Approval in Europe
Lifestyle Coaching Program Launched Today Helps People with Rheumatoid Arthritis Remain Active Read more about Lifestyle Coaching Program Launched Today Helps People with Rheumatoid Arthritis Remain Active
Amgen's Second Quarter 2004 Total Product Sales, Adjusted Earnings and GAAP Earnings Per Share Increased 27 Percent Read more about Amgen's Second Quarter 2004 Total Product Sales, Adjusted Earnings and GAAP Earnings Per Share Increased 27 Percent
Amgen Names Brian Kotzin Vice President, Inflammation Clinical Development and Willard Dere Vice President, General Medicine Read more about Amgen Names Brian Kotzin Vice President, Inflammation Clinical Development and Willard Dere Vice President, General Medicine
Amgen Announces Webcast of Second Quarter Financial Results Read more about Amgen Announces Webcast of Second Quarter Financial Results
